What does the science say? Alpha-2 Macroglobulin (α2M) is a powerful inhibitor of cartilage catabolic factors and slows the progression of osteoarthritis by preventing cartilage breakdown and loss.

The goal of regenerative therapies is to help the body “heal itself.” The objective is to both preserve the function of the body (such as elasticity and range of motion) or restore the strength, resilience, and performance. The questions the incredible team of veterinarians and animal care providers working with Astaria set out to answer was, could the super-concentrate Alpha-2 Marcroglobulin halt cartilage damage at its source? Could the intervention be administered as easily in the field or barn as it could be in the clinic or hospital? Would it produce rapid, remarkable results?
Astaria’s Alpha-2 Regenerative Therapies utilizes a unique process to concentrate plasma proteins from a patient’s own blood and is superior to common Platelet Rich Plasma (PRP) treatments because it removes all of the “junk” (inflammatory cytokines) and retains the therapeutic α2M molecule. More importantly, the AlphaActive Concentrate Process is the only autologous α2M treatment to obtain a U.S patent. Up until the now, other PRP or stem cell therapies fell short – either because of the cumbersome method of administration or the inconsistency of the results.

Alpha-2 Macroglobulin (α2M) is an organically-occurring molecule found in your blood. It is the body’s natural defense against cartilage breakdown by inhibiting the actions of proteins that damage joints and can cause inflammation.

Under a microscope, α2M molecule has unique receptor sites on each side that are surrounded by lobes. The receptor sites attract and captures these destructive elements, at which point the lobes “collapse” around them. With the binding process complete, the body quickly recognizes the protease-α2M complex to then be excreted from the system.

But here is the problem. The size of this complex molecule restricts it from being able to enter the joint or disc space in large enough quantities. It’s there, but it can’t get to the site that may need treatment.

Through our patented and proprietary AlphaActive process, the α2M is isolated and concentrated from the patient’s own blood for reinjection at the injury site. The concentrated serum helps boost natural healing, support tissue restoration and relieve pain.

Over 6,000 patients have been treated to-date, including physicians, and professional athletes. In addition, we have conducted both safety studies with Key Opinion Leaders (KOLs) around the country and most recently completed an equine study with Boise State University.

Interested in providing Alpha2EQ to your patients? Contact us today.